Parasit Host Dis.
2023 Aug;61(3):231-239. 10.3347/PHD.22097.
Recent progress in vaccine development targeting pre-clinical human toxoplasmosis
- Affiliations
-
- 1Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, Core Research Institute, School of Medicine, Kyung Hee University, Seoul 02447, Korea
- 2Department of Medical Zoology, School of Medicine, Kyung Hee University, Seoul 02447, Korea
- KMID: 2545449
- DOI: http://doi.org/10.3347/PHD.22097
Abstract
- Toxoplasma gondii is an intracellular parasitic organism affecting all warm-blooded vertebrates. Due to the unavailability of commercialized human T. gondii vaccine, many studies have been reported investigating the protective efficacy of pre-clinical T. gondii vaccines expressing diverse antigens. Careful antigen selection and implementing multifarious immunization strategies could enhance protection against toxoplasmosis in animal models. Although none of the available vaccines could remove the tissue-dwelling parasites from the host organism, findings from these pre-clinical toxoplasmosis vaccine studies highlighted their developmental potential and provided insights into rational vaccine design. We herein explored the progress of T. gondii vaccine development using DNA, protein subunit, and virus-like particle vaccine platforms. Specifically, we summarized the findings from the pre-clinical toxoplasmosis vaccine studies involving T. gondii challenge infection in mice published in the past 5 years.
